has not previously been examined in a RCT. We report the world's first RCT, TRoMbone, on the safety and feasibility of randomization to systemic therapy plus RP in synchronous oligo-metastatic prostate cancer.
INTRODUCTION AND OBJECTIVES:
To develop a clinical nomogram aimed to predict which patients with recurrent prostate cancer (PCa) could benefit from 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (68Ga-PSMA PET/CT).
METHODS: We retrospectively enrolled 703 PCa patients with biochemical recurrence (BCR) after radical prostatectomy (n[684) and primary radiotherapy (n[19) . Each man underwent 68Ga-PSMA PET/ CT to identify the site of recurrence. Patients were stratified according to different clinical settings of recurrence: first PSA relapse (group 1, n[325), BCR after salvage therapy (group 2, n[241), PSA persistence after primary therapy (group 3, n[76) and disease progression before starting systemic therapies (group 4, n[61) . We assessed the detection rate of 68Ga-PSMA PET/CT in overall population and in each subgroup. Multivariate logistic regressions were used to determine which co-variates (including ISUP group, PSA at 68Ga-PSMA PET/CT, PSA doubling time, ongoing androgen deprivation therapy [ADT] at 68Ga-PSMA PET/CT, time to recurrence and the clinical setting) independently predict a positive 68Ga-PSMA PET/CT. Finally, regression-based coefficients were used to develop a nomogram predicting positive 68Ga-PSMA PET/CT and 200 bootstrap resamples were used for internal validation.
RESULTS: Table 1 reports overall patients characteristics. Median PSA at 68Ga-PSMA PET/CT was 0.7 ng/ml (IQR 0.4-1.3). Overall, 116 (16.5 %) men were on-going with ADT at the time of 68Ga-PSMA PET/CT. Median time to BCR was 21 months (IQR 9-49); median PSA doubling time was 6 months (IQR 4-10). The overall detection rate of 68Ga-PSMA PET/CT was 51.2 %. Table 2 reports PET-CT diagnostic performance among the different groups: detection rate was 40.3 %, 54 %, 60.5% and 86.9 % in group 1, 2, 3 and 4, respectively (p<0.001). At multivariable analysis ISUP grade group, PSA at 68Ga-PSMA PET/CT, PSA doubling time and the clinical setting were found to be independent predictors of positive 68Ga-PSMA PET/CT results (all p 0.04). A nomogram based on covariates included in the multivariate model demonstrated bootstrapcorrected predictive accuracy of 82%.
CONCLUSIONS: Our nomogram could help physician to select patients with different scenario of recurrence who may benefit from 68Ga-PSMA PET/CT restaging.
INTRODUCTION AND OBJECTIVES: Prostate cancer (PC) is the 2nd leading cause of cancer death among US males and accounts for a great proportion of health expenditures. The objective of this study was to evaluate overall survival (OS) and economic outcomes in chemotherapy-naive metastatic castrate resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
METHODS: A retrospective analysis was performed on 3,174 male patients (!18 years) using the Veterans Health Administration (VHA) database. mCRPC patients with evidence of surgical or medical castration, !1 pharmacy claim for abiraterone acetate or enzalutamide (1st claim date [ index date) following surgical or medical castration and with no chemotherapy treatment during the 12 months pre-index
